ROSEN, LEADING INVESTOR COUNSEL, Encourages SeaStar Medical Holding Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – ICU

Core Viewpoint - The Rosen Law Firm is reminding investors who purchased SeaStar Medical Holding Corporation securities during the specified class period of the upcoming lead plaintiff deadline on September 6, 2024, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought SeaStar securities between October 31, 2022, and March 26, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the September 6, 2024 deadline [3][6]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against SeaStar - The lawsuit alleges that SeaStar and/or Legacy SeaStar made false or misleading statements regarding their compliance controls and procedures related to the HDE Application [5]. - It is claimed that the FDA was unlikely to approve the HDE Application in its current form, and the company's regulatory prospects were overstated [5]. - The lawsuit also states that SeaStar downplayed deficiencies in its financial controls and overstated efforts to remediate these issues, leading to potential restatements of previously issued financial statements [5].